Subjects participate in no more than 12 5-hour test sessions, separated by at least 2 days. In the course of the 12 sessions, subjects receive each of three medications - dextromethorphan, scopolamine and rivastigmine - three times and a placebo (pill with no active ingredient) three times. During each session, subjects have TMS measurements, behavioral measurements and electromyography as described in experiment 1.